Use of gnrh agonists to support the luteal phase during infertility treatment
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention concerns the use of an agonist of an hypothalamic hormone for the preparation of a pharmaceutical agent to support the luteal phase during infertility treatment of female mammals and more specifically of women. According to this invention, the pharmaceutical agent is suitable to be used for supporting the luteal phase after a spontaneous ovulation or after stimulation of follicular growth, trigger of final follicular maturation and ovulation with one or several additional agents.
62 Citations
102 Claims
-
1-72. -72. (canceled)
-
73. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent comprising a gonadotrophin releasing hormone (GnRH) agonist which supports the luteal phase, wherein the GnRH agonist is administered either
i) after a spontaneous ovulation, or ii) after stimulation of follicular growth and induction of final follicular maturation and ovulation.
-
98. A method of treating infertility in a female mammal comprising administering a pharmaceutical agent which comprises a GnRH agonist comprising buserelin, which supports luteal phase after stimulation of follicular growth and induction of final follicular maturation and ovulation with one or more additional agents, wherein said buserelin is administered intra-nasally within the first three days following ovulation trigger at a dose of between 50 and 400 μ
- g and at a frequency between three times a day and once every three days for a duration of 7 to 28 days.
- View Dependent Claims (99, 100, 101)
-
102. A kit for the treatment of infertility in female mammals comprising
a) a pharmaceutical agent comprising a GnRH agonist which supports luteal phase, formulated in a dosage and unit required for one cycle of treatment; - and
b) at least one additional agents which triggers final follicular maturation and ovulation.
- and
Specification